Replies to post #283613 on Innovation Pharmaceuticals Inc (IPIX)

[loanranger]

From the Brilacidin Overview:
"Brilacidin has demonstrated broad and robust anti-bacterial, anti-inflammatory and immunomodulatory
properties in Phase 2 trials, across various modes of administration/delivery, in different indications—
Acute Bacterial Skin and Skin Structure Infections (ABSSSI) (intravenous), Inflammatory Bowel Disease
(IBD) (oral tablet for Ulcerative Colitis) and Oral Mucositis (OM) (oral rinse)."

Lots of stuff in that sentence.
Brilacidin hasn't demonstrated broad and robust anti-bacterial, anti-inflammatory and immunomodulatory
properties in Phase 2 trials or any other trials involving "Inflammatory Bowel Disease
(IBD) (oral tablet for Ulcerative Colitis)", has it?

[TheDane]

It’s impressive that Leo and team put this together so quickly and was able to get a signed agreement for testing Brilicidin against Covid-19 at one of the 12 regional bio labs. I’m quite amazed at his ability to seize the moment. Having several successful Phase II trials already done moved Brilicidin and Innovation to the front row and Leo got us noticed! Chance of a successful e is high. IMHO!